{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:58:16Z","timestamp":1789073896575,"version":"build-2803163510"},"reference-count":73,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>The excellent cure rates documented in clinical trials today constitute a very high bar for attempts to de-escalate therapy for early-stage breast cancer (EBC). Moreover, any therapy de-escalation must be made in the context of an optimal multimodal treatment concept as de-escalation of one modality should not be met by escalation of another. In surgery, omission of sentinel lymph node biopsy can now be safely offered for patients with low-risk hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative (HER2\u2013) disease. After neoadjuvant therapy, adapting surgical and\/or radiation therapy (RT) treatment steps to systemic treatment response has already become a reality, yet technical quality assurance is mandatory. Increased use of novel targeted agents in eBC requires adaptation of RT timing that has been addressed by current consensus recommendations. Last but not least, omission of chemotherapy (CTx) is a key question for patients and their physicians in hormone receptor\u2013positive\/HER2\u2013 EBC. In patients with zero to three involved lymph nodes, gene expression assays safely allow CTx omission. Endocrine response assessment, that is, Ki67 determination, after a short 4-week endocrine therapy before surgery adds important information, particularly for premenopausal patients. The overall goal of therapy de-escalation is to reduce treatment burden without compromising patient outcomes. Thus, de-escalation concepts overall, as well as biomarkers used for therapy de-escalation, need to be evidence-based and validated by prospective clinical trials.<\/jats:p>","DOI":"10.1200\/edbk-25-473462","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:59:13Z","timestamp":1750795153000},"source":"Crossref","is-referenced-by-count":7,"title":["Multimodal De-Escalation Strategies in Early Breast Cancer"],"prefix":"10.1200","volume":"45","author":[{"given":"Icro","family":"Meattini","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cM. Serio\u201d, University of Florence, Florence, Italy"},{"name":"Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-161X","authenticated-orcid":false,"given":"Ana","family":"Tecic Vuger","sequence":"additional","affiliation":[{"name":"University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Becherini","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza J.","family":"Epstein","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Berger","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"},{"name":"Department of Surgery, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":true,"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[{"name":"Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01745-8"},{"key":"e_1_3_4_4_2","first-page":"557","article-title":"I. A clinical and histological study of certain adenocarcinomata of the breast: And a brief consideration of the supraclavicular operation and of the results of operations for cancer of the breast from 1889 to 1898 at the Johns Hopkins Hospital","volume":"28","author":"Halsted WS","year":"1898","unstructured":"Halsted WS: I. A clinical and histological study of certain adenocarcinomata of the breast: And a brief consideration of the supraclavicular operation and of the results of operations for cancer of the breast from 1889 to 1898 at the Johns Hopkins Hospital. Ann Surg 28:557-576, 1898","journal-title":"Ann Surg"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-190707000-00001"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70460-7"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181f08f32"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70035-4"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0131"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022152"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020128"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020989"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70207-2"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11470"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01565"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412063"},{"key":"e_1_3_4_17_2","unstructured":"Society of Surgical Oncology: Choosing Wisely. 2016. https:\/\/www.choosingwisely.org\/clinician-lists\/ssosentinel-node-biopsy-in-node-negative-women-70-and-over\/"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002373"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70166-9"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.7827"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00482-X"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414859"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01082-6"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5780"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432442"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00534-X"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8595"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.002"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-PD3-01"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.02.010"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.04.014"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703643"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194790"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2016.10.002"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.12.173"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00896"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2000"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102417"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102586"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00752-5"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001135"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110461"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109805"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110060"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00054-0"},{"key":"e_1_3_4_54_2","unstructured":"NCCN breast cancer (2.2025). https:\/\/www.nccn.org"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1159\/000538596"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00694-5"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488"},{"key":"e_1_3_4_59_2","doi-asserted-by":"crossref","unstructured":"Garber J: GS1-09: OlympiA: A phase 3 multicenter randomized placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer: Longerterm follow. Paper presented at San Antonio Breast Cancer Symposium San Antonio TX December 10-14 2024","DOI":"10.1158\/1557-3265.SABCS24-GS1-09"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS1-05"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00007-3"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02759"},{"key":"e_1_3_4_65_2","unstructured":"Evaluating the addition of adjuvant chemotherapy to ovarian function suppression plus endocrine therapy in premenopausal patients with pN0-1 ER-positive\/HER2-negative breast cancer and an oncotype recurrence score less than or equal to 25 (OFSET). https:\/\/clinicaltrials.gov\/study\/NCT05879926"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0619"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05226-8"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.1558"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt494"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30458-7"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103109"},{"key":"e_1_3_4_72_2","unstructured":"Gluz O: Endocrine therapy and ovarian suppression still an effective treatment strategy in HR+ HER2- early breast cancer. Paper presented at San Antonio Breast Cancer Symposium San Antonio TX December 5-9 2023"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1218"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103987"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:59:14Z","timestamp":1750795154000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473462"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473462","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473462"}}